Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

BACKGROUND: Namilumab (AMG203) is an immunoglobulin G1 monoclonal antibody that binds with high affinity to the GM-CSF ligand. This was a phase 1b, randomized, double-blind study (PRIORA) to assess namilumab in active, mild-to-moderate rheumatoid arthritis (RA). The primary outcome was the safety an...

Descripción completa

Detalles Bibliográficos
Autores principales: Huizinga, T. W. J., Batalov, A., Stoilov, R., Lloyd, E., Wagner, T., Saurigny, D., Souberbielle, B., Esfandiari, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343373/
https://www.ncbi.nlm.nih.gov/pubmed/28274253
http://dx.doi.org/10.1186/s13075-017-1267-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343373/
https://www.ncbi.nlm.nih.gov/pubmed/28274253
http://dx.doi.org/10.1186/s13075-017-1267-3

Ejemplares similares